FOLFIRI is also being tested with MEK162 to evaluate the response rate, clinical benefit and safety parameters in advanced KRAS positive metastatic colorectal cancers (Clinicaltrials.gov Identifier: NCT02613650 (accessed on 24 February 2021)). The gene discussed is KRAS; the disease is metastatic colorectal cancer.